Neurana Pharmaceuticals

Developing a non-sedating treatment for acute muscle spasms

placeSan Diego, California, United States calendar_todayFounded 2013 groups11 employees language neuranapharma.com

Innovation

2 patent families — focus: Human necessities; filing pace slowing. Cited 28 times.

YearFilings
20191
20201
20212

Investor mix

6 investors on record; lead investors include Sofinnova Investments.

Investor typeCountShare
Venture capital350%
Private equity117%
Other / undisclosed233%
Coming soon